Different outcomes for omega-3 heart trials: why?

@article{Deckelbaum2012DifferentOF,
  title={Different outcomes for omega-3 heart trials: why?},
  author={Richard J. Deckelbaum and Philip C Calder},
  journal={Current opinion in clinical nutrition and metabolic care},
  year={2012},
  volume={15 2},
  pages={97-8}
}
DOI:10.1097/MCO.0b013e32834ec9e5 Over the past decade, there has been considerable enthusiasm for using the long-chain omega-3 (n–3) fatty acids (FAs), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) to lower the risk of coronary heart disease and for secondary prevention of myocardial infarction. This makes sense given the multiple biological pathways that are affected by these n–3 FAs. Impacting these pathways seems to be beneficial in preventing dyslipidemia, lowering blood… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
6 Citations
23 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Similar Papers

Loading similar papers…